FDA, PD-1 Inhibitor Sponsors Discussing Real-World Study
Executive Summary
Agency would consider a site-agnostic indication for tumors with high mutation burden if results from the proposed pragmatic clinical practice study were positive.
You may also be interested in...
Immuno-Oncology’s Revolutionary Impact – On US FDA
Unprecedented wave of cancer immunotherapies is in some ways a mirror image of AIDS crisis as FDA explores new tools to accelerate drug development, including modeling techniques and statistical approaches to efficacy. It's an effort to encourage a regulatory revolution in response to a massive number of products in development as opposed to the AIDS-era effort to get products studied.
FDA Oncology Office Looks To Get Better INFORMED Through Big Data
Under the Information Exchange and Data Transformation initiative, existing clinical trial datasets will be standardized and integrated with real-world sources in a new data environment.
FDA Oncology Office Looks To Get Better INFORMED Through Big Data
Under the Information Exchange and Data Transformation initiative, existing clinical trial datasets will be standardized and integrated with real-world sources in a new data environment.